<DOC>
	<DOCNO>NCT00042822</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness FR901228 treat patient myelodysplastic syndrome , acute myeloid leukemia , non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>FR901228 Treating Patients With Myelodysplastic Syndrome , Acute Myeloid Leukemia , Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine pattern adverse clinical experience patient myelodysplastic syndrome , acute myeloid leukemia , intermediate-grade follicular non-Hodgkin 's lymphoma treat FR901228 ( depsipeptide ) . - Determine disease response patient treated drug . - Determine pharmacokinetic pharmacodynamic correlate drug , include measurement serum plasma level , H3 H4 acetylation , apoptosis induction , differentiation , multidrug-resistant ( MDR ) phenotype expression patient . OUTLINE : Patients receive FR901228 ( depsipeptide ) IV 4 hour day 1 5 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow monthly . PROJECTED ACCRUAL : A total 12 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Histologically confirm refractory relapse acute myeloid leukemia ( AML ) Failed anthracyclinebased chemotherapy Ineligible refuse allogeneic stem cell transplantation Elderly patient newly diagnose AML Ineligible refuse standard chemotherapy Histologically confirm highrisk myelodysplastic syndrome Eligible subtypes include : Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia Ineligible refuse allogeneic bone marrow transplantation Histologically confirm intermediategrade nonHodgkin 's lymphoma ( NHL ) Relapsed highdose therapy OR Ineligible allogeneic autologous stem cell transplantation Evaluable lesion radiologic study physical examination Histologically confirm follicular NHL Progressed anthracyclinebased chemotherapy rituximab Evaluable lesion radiologic study physical examination NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin great 1.5 mg/dL ( unless due Gilbert 's syndrome ) SGOT SGPT less 2 time upper limit normal Renal Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular Cardiac ejection fraction great 50 % No cardiac hypertrophy No know conduction heart disease No New York Heart Association class III IV heart disease would make difficult assess patient study participation No significant prior heart disease No significant prior secondary tertiary heart block No significant prior atrial ventricular arrhythmia require therapeutic intervention antiarrhythmic rate control Pulmonary No severe debilitate pulmonary disease would make difficult assess patient study participation Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study participation Potassium ≥ 4.0 mmol/L ( supplementation allow ) Magnesium ≥ 2.0 mg/dL ( supplementation allow ) No concurrent active malignancy except basal cell skin cancer No concurrent significant comorbidity would make difficult assess patient study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics At least 2 week since prior epoetin alfa filgrastim ( GCSF ) At least 4 week since prior cytokine No concurrent immunotherapy Chemotherapy See Disease Characteristics At least 4 week since prior systemic chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other No concurrent investigational agent No concurrent drug may prolong QTc interval FR901228 ( depsipeptide ) may administer 5halflife washout period follow use drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>